Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: A . Left , Representative immunostaining of macrophages in the splenic marginal zone expressing CD169 (red) and Tim4 (green); DAPI nuclear staining (blue). Right , FACS contour plots for CD169 and Tim4 expression in splenic CD45 + CD11b low F4/80 low cells and quantitation of Tim4 expression in CD169 + MMMs; n=4. B . Top Left , FACS pseudocolor plots of circulating Ly6C monocytes with histograms identifying CD169 + and CD169 − populations within Ly6C low monocytes, and corresponding cell quantitation; NTM, normalized to mode. Top Right , principal component analysis of top 500 differentially expressed genes (DEGs) from bulk RNAseq of sorted Ly6C low CD169 − and Ly6C low CD169 + cells, and heat maps with dendrograms for 334 DEGs (q<0.05) between the same sub-populations. Bottom , FACS pseudocolor plots of circulating Ly6C low CD169 + Tim4 + macrophages in naïve and spx mice blood with flow histograms identifying CD64 and MHCII surface expression (in black), together with quantitation of frequency or absolute number of the populations shown; n=5-7, statistics: unpaired t test. C. Top, Representative blood FACS dot plots and quantitation of tdTomato (Tdt) expression in blood Ly6C + monocytes from CX3CR1 CreERT ; Rosa26 tdTomato mice after a tamoxifen (TAM) pulse to induce Cre recombination. Shown are data from several time points after TAM and 14 d after splenectomy (Spx) performed at 26 d post-TAM; *p<0.05, n=3, statistics: unpaired t-test. Bottom , representative FACS plots showing CD169 expression in Tdt+ cells 26 d post-TAM pulse and overlay of the CD169 + Tdt + cells (green) on blood Ly6C + monocytes. D . Top , UMAP plots derived from single cell RNA sequencing of blood leukocytes from 3 naïve mice (∼400K total cells, 11 identified cell clusters), heat map demonstrating CD169 ( Siglec1 ) expression primarily in the monocyte cluster, and quantitative expression of select macrophage genes in cells with and without CD169 expression (adjusted FDR p values are shown). E . Left, FACS plots identifying CD169 + Tim4 + cardiac macrophages in intact and Spx mice, overlay of these macrophages on contour plots of CCR2 and LYVE1 expression (in intact mice), and quantitation of overall LYVE1 and CCR2 expression (n=6). Right , quantitation of frequency and number of cardiac CD169 + Tim4 + LYVE1 low macrophages naïve and Spx C57BL/6 mice; n=5-7/group, statistics: unpaired t test.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Immunostaining, Expressing, Staining, Quantitation Assay, Derivative Assay, RNA Sequencing

Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: A . FACS plots and group quantitation for circulating Ly6C low CD169 + Tim4 + macrophages in sham-operated and MI wild type (WT) C57BL/6 mice 1 d post-MI; n=4/group, statistics: unpaired t test. B. Left , Flow histograms demonstrating surface expression of CCR3 and CCR4 in Ly6C low CD169 + Tim4 + macrophages from the same groups; statistics: unpaired t test, NTM, normalized to mode, y-axis represents cell counts. Right , chemokine gene expression by RT-PCR (normalized to 18s) in the myocardial border zone (BZ) 1 d after MI or sham operation; n=4-5/group, statistics: unpaired t test. *p<0.05, **p<0.01, ***p<0.001 versus sham. C . Left , Circulating Ly6C low CD169 + Tim4 + cell frequency prior to and 1 d after MI in Spx mice; n=9, statistics: paired t test. NS, not significant. D. FACS density plots, histograms, and quantitation of cardiac Ly6C low CD169 + Tim4 + macrophages in WT and Spx mice 1 d post-MI or sham operation; n=4-7/group, statistics: unpaired t test. E . Immunostains and FACS dot plots of splenic CD169 + MMMs (red) 24 h after MI or sham operation, and quantitation of MMM frequency by FACS and spleen weight (Wt); n=5-7/group, statistics: unpaired t test. TL, tibia length. F . Left , FACS dot plots and histograms, and corresponding quantitation, of blood and heart Ly6C low CD169 + Tim4 + Bioparticle + cells from sham and MI mice given 10 mg/kg Texas Red-conjugated bioparticles i.v. 3 h before sacrifice; n=3-4/group, statistics: unpaired t test for blood and non-parametric Mann-Whitney U test for heart (non-normal distribution). Right, quantitation of splenic BioParticle + MMMs in the same experimental mouse groups; statistics: unpaired t test.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Quantitation Assay, Expressing, Gene Expression, Reverse Transcription Polymerase Chain Reaction, MANN-WHITNEY

Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: A Left , Parabiosis schema joining CD45 isotype-mismatched host (spleen-intact or after splenectomy [Spx]) and donor parabiont mice, with MI induced in the host. Middle and Right , FACS plots and quantitation of donor chimerism in host mouse blood (total CD45 + leukocytes) and heart (Ly6C low CD169 + macrophages) in spleen-intact and Spx host mice 48 h after MI. n=4-7/group, statistics: unpaired t-test. B Top Left , Parabiosis schema joining CD169 DTR host and donor parabiont MaFIA mice, with host mice given either vehicle or diphtheria toxin (DT) at the time of MI. Right , Representative FACS dot plots of donor GFP + CD169 + macrophages in 48 h post MI hearts from host mice and flow histograms of CD169 expression in GFP + CD64 + MHCII + Tim4 + cells delineated as NTM or cell counts. Bottom Left , quantitation of GFP + frequency in host cardiac CD169 + Tim4 + macrophages and total CD169 + Tim4 + cells as a percentage of all autofluorescent(Auto) + macrophages in vehicle and DT treated host MI mice; n=3-4/group, statistics: unpaired t test. C. Left , Parabiosis schema joining CD169 DTR host mice and either spleen-intact or Spx MaFIA donor parabionts, with host mice given DT at the time of MI to deplete CD169 + macrophages. Right , Example FACS dot plots and quantitation of donor CD45 + Auto + CD64 + MHCII + GFP + CD169 + Tim4 + macrophages in the host MI heart 48 h post MI; n=3-4/group, statistics: unpaired t test.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Quantitation Assay, Expressing

Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: A . Left, FACS pseudocolor plots of cardiac CD169 + Tim4 + macrophages and separation based on LYVE1 surface expression in naïve and 1 d post-MI mice. Right , quantitation of LYVE1 hi and LYVE1 low CD169 + Tim4 + macrophages in hearts from naïve and 1 d post-MI mice. n=4-6/group; statistics: unpaired t test. B . Heat map of 462 significant (p adjusted<0.05) DEGs by RNAseq analysis in sorted LYVE1 hi and LYVE1 low CD169 + Tim4 + cardiac macrophages 1 d post-MI. C. PCA plots using the top 500 DEGs after rlog transformation of RNAseq data from these macrophages sorted from the indicated sites in naïve and 1 d post-MI mice. D. Left , Flow histograms depicting LYVE1 surface expression on cardiac CD169 + Tim4 + macrophages (green) and total Autofluorescence + CD64 + MHCII + macrophages (brown) in WT and Spx mice, 1 d post-MI. Right , FACS quantitation of LYVE1 hi and LYVE1 low CD169 + Tim4 + macrophages in the hearts of WT and Spx mice, 1 d post-MI; n=5-6/group. Statistics: unpaired t test. E. Representative confocal micrograph of border zone (BZ) myocardium immunostained for CD169 (red) and Tim4 (green) 1 d post-MI in WT and Spx mice; nuclear staining with DAPI (blue). Scale bar, 200 μm. Inset shows magnified images of CD169 and Tim4 staining. Yellow arrows indicate double positive cells; scale bar 10 μm.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Expressing, Quantitation Assay, Transformation Assay, Staining

Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: FACS plots and quantitation of Ly6C low CD169 + Tim4 + macrophages and total Ly6C low cells in blood ( A ) and in heart ( B ) 1 d post-MI in wild-type (WT) and splenectomized (Spx) WT mice, and CD169 DTR mice given diphtheria toxin (CD169 DTR /DT) at the time of MI; n=5-7/group, statistics: one-way ANOVA, Bonferroni post-test. Isotype antibody is shown in gray. C . FACS plots and group data for blood CD45 + CD11b + Ly6G + neutrophils and ICAM-1/CD54 + neutrophils 1 d post MI in WT, Spx, and CD169 DTR /DT mice; n=6-8/group; statistics: one-way ANOVA, Bonferroni post-test. D . Left, Representative confocal images of immunofluorescent Ly6G staining in WT, Spx, and CD169 DTR /DT hearts 1 d post-MI demonstrating Ly6G + neutrophil (red) infiltration (arrows); nuclear staining with DAPI (blue). Scale bar 20 μm. Right , FACS plots and corresponding quantitation of cardiac CD45 + CD11b + Ly6G + neutrophils (red) and annexin V + apoptotic neutrophils (blue) in the same groups 1 d post-MI; n=3-4/group, statistics: one-way ANOVA, Dunnett’sT3 post-test. E . FACS density plots for Lin − c-kit + CD34 + CD16/32 + granulocyte monocyte precursors (GMPs) in bone marrow from WT, Spx, and CD169 DTR /DT mice 1 d post MI, together with quantitation. Flow gates were based on isotype antibody control. n=5-7/group; statistics: one-way ANOVA, Tukey’s post-test. F . Left , Representative FACS dot plots identifying cardiac neutrophils as CD11b + Ly6G + cells in WT mice and as Ly6G + tdTomato + cells in Catchup mice at baseline and 1 d post-MI. Right Top , Representative histograms of Ly6G and tdTomato fluorescence intensity in heart mononuclear cells from the same groups. Right Bottom , FACS dot plots gated on cardiac CD169 + Tim4 + macrophages illustrating tdTomato expression in Catchup mice 1 d post-MI. Auto, autofluorescence. G . Representative FACS histograms of intracellular IL4 and IL10 staining in cardiac Ly6C low cells 1 d post MI in WT, Spx and CD169 DTR /DT mice, together with cell quantitation of the Ly6C low subsets. N=6-7/group; statistics: one-way ANOVA, Bonferroni post-test. H . Representative FACS pseudocolor plots for intracellular TGFβ and IL10 staining in cardiac CD169 + macrophages 1 d post MI in WT and Spx mice, with accompanying quantitation; n=4-5/group, statistics: unpaired t test.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Quantitation Assay, Staining, Control, Fluorescence, Expressing

Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: A . Kaplan-Meier survival curves over 10 d following MI or sham operation in WT, Spx, and CD169 DTR /DT mice, and after MI in CD45.2 Spx mice with adoptive transfer of naïve splenic CD169 + Tim4 + cells from syngeneic CD45.1 WT mice 24 h post-MI (Spx-MI+AT). Statistical comparisons: log-rank test. B . Gross images of post-MI cardiac rupture with hemothorax or hemopericardium, and Kaplan-Meier curves for freedom from rupture over 10 d post-MI in WT, Spx, CD169 DTR /DT, and Spx-MI+AT mice. Statistical comparisons: log-rank test. C . Left , Representative post-mortem whole hearts and end-diastolic long-axis 2-dimensional echocardiograms from WT-MI, Spx-MI, CD169 DTR /DT-MI and Spx-MI+AT mice (10 d post-MI). Right , Quantitation of LV ejection fraction (EF) and end-diastolic and end-systolic volume (EDV and ESV) at 10 d post-MI; n=4-6/group, statistics: one-way ANOVA, Bonferroni post-test. D . Left , Representative confocal images of immunofluorescent staining for CD206 (green) and iNOS (red) in the heart infarct border zone (BZ) from WT-MI, Spx-MI, CD169 DTR /DT-MI, and Spx-MI+AT mice 10 d post-MI. DAPI (blue) nuclear staining. iNOS + CD206 + cells appear yellow. Higher magnification is shown in the middle panel. Right , quantitation of iNOS + CD206 + and iNOS − CD206 + cells/mm 2 in the hearts. N=3/group, statistics: one-way ANOVA, Bonferroni post-test. NS, not significant. E . Top Left , Confocal images of MMP-9 immunostaining (red) in infarct BZ of hearts from WT-MI, Spx-MI, CD169 DTR /DT-MI, and Spx-MI+AT mice 10 d post-MI. Nuclear staining with DAPI (blue). Top Right , Quantitative group data for total MMP-9 mean fluorescence intensity per region of interest (ROI). AU, arbitrary units. N=4/group, statistics: one-way ANOVA, Bonferroni post-test. Bottom , Representative Masson’s trichrome stains of infarcted hearts (10 d post-MI) from the same groups demonstrating MI border zone (BZ) fibrosis, together with BZ fibrosis quantitation. n=4/group; statistics: one-way ANOVA, Bonferroni post-test. F . FACS quantitation of Ly6C hi blood monocytes and serum IL-10 levels in WT-MI, Spx-MI, CD169 DTR /DT-MI, and Spx-MI+AT mice at 10 d post-MI. N=4-7/group, statistics: one-way ANOVA, Bonferroni post-test.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Adoptive Transfer Assay, Quantitation Assay, Staining, Immunostaining, Fluorescence

Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: A . Protocol for LXRα agonist T0901317 treatment (40 mg/kg i.p.) from 1 d prior to 5 d post-MI, with 10 d post-MI follow-up, in WT and Spx mice. B . FACS contour plots and quantitation of cardiac CD169 + Tim4 + macrophages 1 d post-MI and blood CD169 + Tim4 + macrophages 10 d post-MI in untreated and T0901317-treated WT and Spx mice. N=5-6/group, statistics: one-way ANOVA, Bonferroni post-test. C . Kaplan-Meier survival curves post-MI in untreated and T0901317-treated WT and Spx mice. Statistical comparisons by log-rank test, group sizes as indicated. D . Representative end-diastolic long-axis 2-dimensional echocardiograms and group data for LV ejection fraction (EF) and end-diastolic and end-systolic volume (EDV and ESV) in the same mouse groups at 10 d post-MI; n=5-10/group, statistics: one-way ANOVA, Bonferroni post-test. E . Top , Kaplan-Meier survival curves over 8 w post-MI in WT mice treated with either vehicle or T0901317 from 1 d before MI to 5 d post-MI (statistical comparison by log-rank test, n=12-17/group as indicated) and group data for LVEF, LVEDV, LVESV, and normalized heart and lung weight at 8 w post-MI; n=8-9/group for echocardiography, n=4-7/group for gravimetry. Statistical comparisons: unpaired t test. HF, heart failure; TL, tibia length; NS, not significant. Bottom Left , Representative Masson’s trichrome staining of LV short-axis sections (2x magnification) and infarct border zone (BZ, scale bar 500 μm), along with quantitation of cardiac fibrosis (BZ and remote zone [RZ], blue staining) in vehicle- and T0901317-treated WT HF mice. Also shown are confocal images of immunofluorescent staining for CD206 (green) and iNOS (red) in the RZ of hearts from vehicle-and T0901317-treated HF mice (8 w post-MI) and quantitation of iNOS + CD206 + and iNOS − CD206 + macrophages (Mφ) per mm 2 . Double positive (CD206 + iNOS + ) cells appear yellow (arrows). DAPI (blue) was used for nuclear staining. N=4-8/group, statistics: unpaired t test. Bottom Right , Representative FACS contour plots to identify Ly6C hi monocytes in vehicle- and T0901317-treated WT HF mice (8 w post-MI), and corresponding quantitation. N=5-10/group, statistics: unpaired t test.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Quantitation Assay, Comparison, Staining

Journal: medRxiv

Article Title: Splenic CD169 + Tim4 + Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction

doi: 10.1101/2024.08.09.24311769

Figure Lengend Snippet: A . FACS plots and characterization of human CD45 + CD14 + HLA- DR + CD64 + CD169 + Tim4 + circulating macrophages from a subject with acute STEMI. The accompanying overlaid contour plot illustrates CD14 + HLA-DR + (red) and CD64 + CD169 + Tim4 + (green) subsets superimposed on all CD45 + leukocytes in an SSC-A versus FSC-A gate. B . Top , FACS gating strategy for sorting CD45 + CD14 + HLA-DR + CD169 + cells from human peripheral blood for further characterization using ImageStream analysis. Bottom , ImageStream visualization of FACS-sorted CD45 + CD169 + blood cells from STEMI patients and control subjects undergoing elective percutaneous coronary intervention (PCI), and group data for size distribution of CD169 + cells; scale bar 10 μm. C . FACS contour plots and quantitation of circulating CD45 + CD14 + HLA-DR + CD64 + CD169 + Tim4 + macrophages in STEMI and control PCI subjects. n=11-14/group, statistics: unpaired t test.

Article Snippet: Cell suspensions were incubated with anti-mouse CD16/32 (clone 93, BioLegend) for 10 min at 4°C to block Fcγ receptors, and then stained for 60 minutes in staining buffer with anti-mouse fluorochrome-conjugated antibodies in panel appropriate combinations for specific experiments as follows: Ly6C-PE-Cy7 (HK1.4, eBioscience), Ly6C-PE Vio770 (1G7.G10, Miltenyi Biotec), CD45.1-FITC (A20, Miltenyi Biotec), CD45.2-PE (104, BD Biosciences), CD169-PE (REA197, Miltenyi Biotec; and 3D6.112, BioLegend), CD11b-Alexa Fluor 700 (M1/70, eBioscience), Tim4-Alexa Fluor 647 (RMT4-54, BioLegend), Gr1/Ly6G-eFluor 450 (RB6-8C5, eBioscience), F4/80-PerCP-Cy5.5 (BM8, eBioscience), MARCO-FITC (ED31, Novus Biologicals), CD45-600 Super Bright (30-F11, eBioscience), CD45-PE-Cy7 (30-F11, BD Biosciences), LYVE1 Alexa Fluor 488 (ALY7, eBioscience), CD45-605 NC (30-F11, eBioscience), CD54(ICAM-1)-PE (eBioKat-1, eBioscience), MHCII (I-A/I-E)-APC-eFluor780 (M5/114.15.2, eBioscience), TGFβ1-APC (TW7-16B4, BioLegend), CD54-FITC (YN1/1.7.4, BioLegend), CD169-PerCP/Cy5.5 (3D6.112, BioLegend), CD169-PE (3D6.112, BioLegend), CD64-Brilliant Violet 605 (X54-5/7.1, BioLegend), CD206-FITC (MR5D3, AbD Serotech), CD45-eVolve 605 (30-F11, eBioscience), CD206-Alexa Fluor 647 (MR5D3, Bio-Rad), IL17A-Alexa Fluor 700 (TC11-18H10.1, BioLegend), CD34-Alexa Fluor 647 (SA376A4, BioLegend), CD117(c-kit)-PE/Cy7 (ACK2, BioLegend), NOS2-TRITC (N-20, Santa Cruz Biotechnology), and CD16/32-PE (93, BioLegend, without pre-Fcγ receptor blocking).

Techniques: Control, Quantitation Assay

Journal: Communications Biology

Article Title: Slow viral propagation during initial phase of infection leads to viral persistence in mice

doi: 10.1038/s42003-021-02028-x

Figure Lengend Snippet: a , b C57BL/6 mice were infected with 2 × 10 4 pfu LCMV-WE (WE), and LCMV-Docile (Docile). At day 2 post-infection, spleen tissues were stained for LCMV antigen NP, CD169, CD11c, and B220 ( a ) or CD90.2, F4/80, and Ly6c ( b ) (representative sections are shown ( n = 4) scalebar = 20 µm). C57BL/6 mice were infected with LCMV-WE (WE), LCMV-Docile (Docile), or WE together with Docile (WE + Docile). c , d At day 2 post-infection, numbers of c splenic cDC (CD11c + MHC-II + ) and pDC (B220 + Siglec-H + ) were determined ( n = 9, gating strategy is shown in Supplementary Fig. ). d Co-stimulatory molecules CD40, CD80, and CD86 were measured on splenic cDC ( n = 6). e Serum IFN-α concentrations were determined at the indicated time post-infection ( n = 9). f Serum IL-6, g serum TNF-α, h serum IL-1β concentrations were measured at the indicated timepoints ( n = 5). (Error bars show SEM, * p < 0.05, ** p < 0.01, *** p < 0.001, and ns indicates statistically not significant between the indicated groups).

Article Snippet: Antibodies against CD169 (Bio-Rad), CD11c, B220, CD90.2, F4/80, Ly6C (ebioscience), donkey-anti-rat secondary antibody (jackson immunoresearch), and self-made anti-LCMV monoclonal antibody (Clone: VL-4), were used.

Techniques: Infection, Staining

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

doi: 10.1177/1352458517698759

Figure Lengend Snippet: Figure 1. CD169-expressing phagocytes are increased in the circulation and CNS of EAE animals. (a and b) Spinal cord tissue of EAE animals (20 dpi) stained for (a) CD169 and Iba1 or (b) CD169 and CD11b/c (both 20× magnification). (c) Spinal cord tissue of EAE animals (30 dpi) stained for CD169 and Iba1 (40× magnification). (d) Quantification of the amount of CD169+ cells per image and (e) the percentage of Iba1+ cells expressing CD169 in spinal cord tissue of control and EAE mice (acute (20 dpi) and chronic phase (30 dpi)). For quantification, 20 images per animal with 9 animals per time point were used (20× magnification). (f and g) PBMC isolated from control (n = 7) and EAE mice (acute phase (20 dpi), n = 6; chronic phase (30 dpi), n = 9) were stained for CD14 and CD169. Flow cytometry was used to assess the (f) % of CD14+ cells expressing CD169 and (g) the abundance of CD169 on these cells. Data are presented as mean ± SEM.

Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

Techniques: Expressing, Staining, Control, Isolation, Flow Cytometry

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

doi: 10.1177/1352458517698759

Figure Lengend Snippet: Figure 2. Transient depletion of CD169-expressing cells reduces EAE severity. (a) CD169-DTR mice and WT mice were sacrificed 2 or 8 days after intraperitoneal DTR administration. Splenic sections were stained with CD169 and DAPI (20× magnification). One representative image is shown. (b) Spinal cord tissue of PBS- and DT-treated CD169- DTR EAE animals (30 dpi) stained for CD169 and CD11b/c (20× magnification). EAE animals were treated with PBS or DT every other 5 days, starting 5 dpi. (c) Images show CD169 immunoreactivity on phagocytes 5 days post the last DT treatment. MOG-immunized CD169-DTR animals were treated every other 5 days (arrows) starting 5 dpi with PBS (n = 4; black) or diphtheria toxin (DT, n = 8). Neurological score and weight was assessed daily. Data represent the mean ± SEM. (d) The cumulative disease index and (e) disease onset of immunized CD169-DTR mice treated with PBS or DT. Data represent the mean ± SEM.

Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

Techniques: Expressing, Staining

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

doi: 10.1177/1352458517698759

Figure Lengend Snippet: Figure 3. The number of circulating CD169+ phagocytes is increased in MS patients. (a and b) PBMCs isolated from MS patients (n = 57) and healthy controls (n = 19) were stained for CD14 and CD169. Flow cytometry was used to assess (a) the percentage of CD14+ cells expressing CD169 and (b) the abundance of CD169 on these cells. MS patients were subdivided based on their treatment regime: no treatment (n = 19), natalizumab (n = 10), beta-interferon (n = 22), and alemtuzumab (n = 6). Data are presented as mean ± SEM.

Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

Techniques: Isolation, Staining, Flow Cytometry, Expressing

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

doi: 10.1177/1352458517698759

Figure Lengend Snippet: Figure 4. CD169 is highly expressed in MS brain tissue. (a–g) CNS tissue of non-neurological controls (white matter) and (chronic) active MS lesions were stained for CD169. Overview images of (a) an active and (b) chronic active MS lesion (2.5× magnification). (c) NAWM of non-demented control stained for CD169 (40× magnification). Representative images of (d) perilesional area of active MS lesion, (e) lesion center of active MS lesion, (f) perivascular cuff of active MS lesion, (g) active rim of chronic active MS lesion, and (h) inactive center of chronic active MS lesion (all 40× magnification).

Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

Techniques: Staining, Control

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Article Title: CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.

doi: 10.1177/1352458517698759

Figure Lengend Snippet: Figure 5. CD169 is highly expressed on myelin-containing phagocytes in MS lesions. (a) Fluorescent staining of active MS lesion (green, Iba1; red; CD169; 20× magnification). (b) Fluorescent staining of active MS lesion (green, PLP; red; CD169; 20× magnification). (c) Quantification of the percentage of Iba1+ cells expressing CD169 in active MS lesions. For quantification, 10 images per tissue or MS lesions were used (20× magnification). Data are presented as mean ± SEM.

Article Snippet: For flow-cytometric analysis of PBMCs, the following antibodies were used: rat-anti-mouse CD169 FITC (Abd Serotec), rat-anti mouse CD14 PE (eBioscience, San Diego, CA), mouse anti-human CD14 PerCP (BD Biosciences, Erembodegem, Belgium), mouse anti-human CD56 PE-Cy7 (BD biosciences), mouse anti-human CD169 FITC (Abd Serotec), and mouse anti-human CD7 PE (BD Biosciences).

Techniques: Staining, Expressing

Journal: Vaccines

Article Title: Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide

doi: 10.3390/vaccines9070692

Figure Lengend Snippet: Effect of Mag-Pam2Cys on moMΦ surface marker expressions. Then, 24 h post-stimulation with scalar doses of Mag-Pam2Cys (10 or 100 ng/mL), surface expression of CD14, MHC II DR, CD25, CD163, MHC I, and CD169 were assessed by flow cytometry. In Panel ( a ), mean fluorescence intensity (MFI) data are presented as fold-change relative to the untreated control (moMΦ). In Panel ( b ), percentages of positive cells are shown. For both Panels, mean data and SD from four independent experiment using different blood donor pigs are displayed. Values of Mag-Pam2Cys-treated samples were compared to the untreated control (moMΦ) using a one-way ANOVA followed by a Dunnett’s multiple comparison test. *** p < 0.001, ** p < 0.01, * p < 0.05.

Article Snippet: Cells were then resuspended in 0.1 mL of PBS, and staining with monoclonal antibodies was performed using mouse anti human CD14-PerCP (Tuk4; Miltenyi Biotec, Bergisch Gladbach, Germany), mouse anti pig MHC class II DR-FITC (2E9/13, Bio-Rad Antibodies, Kidlington, UK), MHC class I (JM1E3, Bio-Rad Antibodies), CD163-PE (2A10/11, Bio-Rad Antibodies), CD169-FITC (MCA2316F, Bio-Rad Antibodies), and CD25 (K231.3B2, Bio-Rad Antibodies).

Techniques: Marker, Expressing, Flow Cytometry, Fluorescence, Control, Comparison

Journal: Vaccines

Article Title: Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide

doi: 10.3390/vaccines9070692

Figure Lengend Snippet: Modulation of moMΦ surface marker expressions by Mag-Pam2Cys and classical M1 polarizing factors. Porcine moMΦ were left untreated (MΦ) or stimulated with Mag-Pam2Cys (100 ng/mL) or IFN-γ + LPS (M1). At 24 h post-stimulation, surface expression of CD14, MHC II DR, CD25, CD163, MHC I, and CD169 were assessed by flow cytometry. In Panel ( a ), mean fluorescence intensity (MFI) data are presented as fold-change relative to the untreated control (moMΦ). In Panel ( b ), percentages of positive cells are shown. For both Panels, mean data and SD from three independent experiments using different blood donor pigs are displayed. Values of Mag-Pam2Cys-treated samples were compared to bona fide moM1 (M1), using a Mann–Whitney test. *** p < 0.001, ** p < 0.01, * p < 0.05.

Article Snippet: Cells were then resuspended in 0.1 mL of PBS, and staining with monoclonal antibodies was performed using mouse anti human CD14-PerCP (Tuk4; Miltenyi Biotec, Bergisch Gladbach, Germany), mouse anti pig MHC class II DR-FITC (2E9/13, Bio-Rad Antibodies, Kidlington, UK), MHC class I (JM1E3, Bio-Rad Antibodies), CD163-PE (2A10/11, Bio-Rad Antibodies), CD169-FITC (MCA2316F, Bio-Rad Antibodies), and CD25 (K231.3B2, Bio-Rad Antibodies).

Techniques: Marker, Expressing, Flow Cytometry, Fluorescence, Control, MANN-WHITNEY

Journal: iScience

Article Title: Immunometabolic adaptation in monocytes underpins functional changes during pregnancy

doi: 10.1016/j.isci.2024.109779

Figure Lengend Snippet:

Article Snippet: CD169 human antibody (clone 7-239) , Miltenyi , Cat#130-098-654; RRID: AB_2655545.

Techniques: Recombinant, Adhesive, Sequencing, Modification, DC Protein Assay, Staining, Imaging, Enzyme-linked Immunosorbent Assay, Bicinchoninic Acid Protein Assay, Gene Expression, Software, Saline

Journal: Cell

Article Title: Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches

doi: 10.1016/j.cell.2021.12.018

Figure Lengend Snippet: Combination of CITE-seq, scRNA-seq, snRNA-seq, and spatial analyses enables generation of a human liver atlas and identification of bona fide human KCs, related to Figure 4 (A and B) Top DEGs (A) and DEPs (B) for the cell types from Figure 4 B. (C) Distinct profiles of cells or nuclei within the UMAP depending on isolation protocol used; 152,535 cells from ex vivo digestions and 15,063 nuclei. (D) Proportion of each cell type per patient profiled. (E) Proportion of indicated cell types as a % of total CD45 + cells calculated from ex vivo digested samples per surgery type. Ch; cholecystectomy, Re; resection, GB; gastric bypass. ∗ p < 0.05; one-way ANOVA with Bonferroni post-test. (F) Mapping of Visium UMAP zonation patterns onto tissue sections from patient H35 and H37. (G) Expression of indicated zonation genes in patients H35–H38 assessed by Molecular Cartography. (H and I) Expression of indicated proteins by MICS 100-plex protein analysis in the healthy (H) and steatotic (I) human liver. (J) Murine myeloid cells (cDC1s, cDC2s, Mig. cDCs, Macs, monocytes, and monocyte-derived cells; 42,922 cells) from mice fed the SD or WD for 24 or 36 weeks were isolated from Figure S5 J and re-clustered with TotalVI. (K) Distribution of cells in UMAP originating from SD- (purple) or WD- (yellow) fed mice. (L) Proportion of indicated cell types arising from mice fed the SD (purple) or WD (yellow). (M and N) Flow cytometry analysis of indicated cell populations in SD and WD-fed mice (24 weeks). Representative gating strategies (M) and absolute number of indicated populations (N). ∗ p < 0.05, ∗∗ p < 0.01 Student’s t test. Data are from 2 independent experiments with n = 5–6 per diet. (O and P) Top DEGs (O) and DEPs (P) for cell types from Figure 4 H. (Q) Top 25 Murine KC genes as expressed by the human myeloid cell clusters. (R) Mapping of KC signature onto Visium trajectory for healthy (purple) and steatotic (orange) livers. (S) Expression of VSIG4 mRNA within human myeloid cells. (T) Expression of VSIG4 (red) and CD163 (gray, top) or CD169 (gray, bottom) by MICS analysis in healthy human liver. (U) Representative images showing KC location (red) as assessed by MICS analysis in the healthy (left) and steatotic (right) human liver. PV, portal vein; CV, central Vein, dashed line indicates zones of steatosis. (V) Representative image of CD68 and CD163 staining in 10–15-year-old human liver paraffin sections. Image is representative of 6 different patients. (W) In silico gating strategy to isolate distinct myeloid cell populations identified from CITE-seq data. (X) Expression of VSIG4 and FOLR2 by live CD45 + cells also expressing CD14 in indicated human liver biopsies by flow cytometry. Data are representative of 21 biopsy samples analyzed.

Article Snippet: Anti-Human CD169 (REA1176) PE , Miltenyi Biotec , 130-121-115; RRID: AB_2783985.

Techniques: Isolation, Ex Vivo, Expressing, Derivative Assay, Flow Cytometry, Staining, In Silico

Journal: Cell

Article Title: Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches

doi: 10.1016/j.cell.2021.12.018

Figure Lengend Snippet:

Article Snippet: Anti-Human CD169 (REA1176) PE , Miltenyi Biotec , 130-121-115; RRID: AB_2783985.

Techniques: Purification, Recombinant, Staining, cDNA Synthesis, Gene Expression, Software, Microscopy

Journal: Cell reports

Article Title: Identification of an Early Unipotent Neutrophil Progenitor with Pro-Tumoral Activity in Mouse and Human Bone Marrow

doi: 10.1016/j.celrep.2018.07.097

Figure Lengend Snippet: (A) Flow cytometry analysis of healthy human BM uncovers a heterogeneous Lin−CD66b+CD117+ hNeP fraction. Dump antibody cocktail contains antibodies against markers that are expressed by: HSC (CD90 (Thy1)), lymphocytes and their progenitors (CD3, CD19, CD56, CD161, CD7, CD127 (IL-7Rα)), Erythrocytes and their progenitors (CD41, CD235a (Glycophorin A)), Eosinophils/Basophils and their progenitors (Siglec 8, FcεRIα, , CD125 (IL-5Rα)), CMP/GMP and monocyte progenitors (CD123 (IL-3Rα)), DCs and macrophages (CD11c, CD169). (B) ScRNA-Seq analysis of Lin−CD66b+CD117+ hNeP cells reveals two major subpopulations, Subset A and Subset B. 20,000 hNeP cells were FACS sorted from healthy human BM for scRNA-Seq. Heatmap shows top 40 differentially expressed genes in each cluster. Log2 Fold Change of each gene expression is relative to the entire dataset. 2 biological triplicates, 2 technical replicates. (C) Lin−CD66b+CD117+ hNeP were divided into CD34+ subset and CD34−subset by flow cytometry. Confocal microscopy was used to detect Ki67 localization (red) within the nuclei (blue) in CD34+ subset and CD34−subset using antibodies to Ki67 and Hoechst. IgG stained cells served as negative control. Bar: 5µm.

Article Snippet: Antibodies for flow cytometry were purchased from commercial sources as follows: anti-mouse CD3ε (145–2C11; BD Biosciences); anti-mouse CD19 (1D3; BD Biosciences); anti-mouse CD161 (PK136; eBiosciences); anti-mouse F4/80 (T45–2342; BD Biosciences); anti-mouse CD11c (HL3; BD Biosciences); anti-mouse CD45 (30-F11; BioLegend); anti-mouse CD45.1 (A20; BioLegend); anti-mouse CD45.2 (104; BioLegend); anti-mouse CD117 (c-kit) (2B8; BioLegend); anti-mouse Ly6A/E (Sca-1) (D7; BioLegend); anti-mouse CD16/32 (FcγRIII/II (93; BioLegend); anti-mouse/human CD11b (M1/70; BioLegend); anti-mouse CD115 (M-CSFR) (AFS98; BioLegend); anti-mouse Ly6G (1A8; BioLegend); anti-mouse Ly6C (HK1.4; BioLegend); anti-mouse Siglec F (E50–2446; BD Biosciences); anti-mouse FcεRIα (MAR-1; BioLegend); anti-mouse Ki67 (SolA15; eBiosciences); anti-human CD45 (2D1; BioLegend); anti-human CD3ε (HIT3a; BD Biosciences); anti-human CD3ε (OKT3; BD Biosciences); anti-human CD7 (MT701; BD Biosciences); anti-human CD161 (HP-3G10; BioLegend); anti-human CD56 (B159; BD Biosciences); anti-human CD19 (HIB19; BD Biosciences); anti-human CD127 (A019D5; BioLegend); anti-human Siglec 8 (7C9; MACS Miltenyi Biotec); anti-human FcεRIα (AER-37; BioLegend); anti-human CD235a (GA-R2; BD Biosciences); anti-human CD41 (HIP8; BD Biosciences); anti-human CD169 (7–239; BD Biosciences); anti-human CD69 (FN50; BioLegend); anti-human CD11c (B-ly6; BD Biosciences); anti-human CD90 (5E10; BioLegend); anti-human CD86 (IT2.2; BioLegend); anti-human CD66b (G10F5; BioLegend); anti-human CD34 (581; BD Biosciences); anti-human CD117 (YB5.B8; BD Biosciences); anti-human CD38 (HB-7; BioLegend); anti-human CD15 (W6D3; BioLegend); anti-human CD49d (9F10; BioLegend); anti-human CD10 (Hl10a; BioLegend); anti-human CD101 (BB27; BioLegend); anti-human CD16 (3G8; BioLegend).

Techniques: Flow Cytometry, Expressing, Confocal Microscopy, Staining, Negative Control